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The conservation of structure across homolog proteins often diffuses the impact of drug-based inhibition by promoting alternative protein-ligand associations that may lead to toxic side effects. However, sticky packing defects are typically not conserved across homologs, making them valuable a priori targets to enhance specificity. By introducing a homology to quantify packing differences among proteins, we enable a previously undescribed strategy for the design of highly selective drug inhibitors involving ligands that wrap nonconserved packing defects. The selectivity of these ligands is validated by performing affinity assays on a cancer-related pharmacokinome. Minor reengineering of a powerful inhibitor guided by wrapping differences across its target kinome can selectively direct its impact toward a specific kinase. Thus, nonconserved packing defects may be used as selectivity switches across homolog targets, using spatial displacements of packing defects across aligned protein structures.
dehydron ͉ hydrogen bond C reating inhibitors to target specific proteins without undesirable side effects is a major goal of drug design. Drug-induced signaling or enzymatic inhibition may have at least two kinds of side effects: the targeted protein may act along pathways other than the one of interest, or paralog proteins may associate with the inhibitor. This work presents a way to minimize interactions with paralogs. To reduce possible side effects, we use characteristics of protein-ligand interactions that are not preserved across paralogs, despite the similarity of their 3D structures (1-3). The specific feature here is a kind of packing defect that is important for protein association (4, 5) and especially for drug design (6) . Quantifiable features of these interactions let us introduce a phylogeny that we can use to predict side effects and modulate the inhibitory impact of a drug.
Considerable research has helped clarify many aspects of protein-ligand interaction (7) . Various methods enable one to predict such interactions, such as the assessment of packing defects (8), analysis of protein-interface geometry (9), docking dynamics (10), modeling free energy (11), computational molecular probing (12) , sequence threading (13) , and learning-theory approaches (14) . The first four methods are based on properties of protein interfaces; the latter two are based only on sequences and attempt to ''learn'' features encoded in those sequences. Combined methodologies also are being developed (14) . Some of these techniques seek features of protein surfaces that promote protein-protein interactions. We show here how features with a quantifiable metric can be used to compare paralogs for selective drug development.
To function, soluble proteins require relatively stable structures, a condition often requiring associations (15) (16) (17) . Isolated structures with packing defects arising as poorly protected hydrogen bonds (H-bonds) typically do not prevail in water (3, 18) . Conversely, such defects are inherently sticky, promoting removal of surrounding water through protein associations (8) . We show here that such packing defects may be targeted to develop a previously undescribed type of highly selective drug-based inhibitor. Known structures of protein-inhibitor complexes (19) (20) (21) (22) (23) (24) provide the foundation to design inhibitors as wrappers or protectors of packing defects.
Although folds are typically conserved across homolog proteins, packing defects are often not conserved (3). Thus, side effects resulting from off-target ligand binding may be minimized by selectively targeting nonconserved packing defects with the guidance of a measure of packing proximity between structures. This work reveals that packing defects may act both as selectivity filters operative across homolog proteins and selectivity switches to reengineer a protein inhibitor to redirect its impact toward another target. This latter role takes advantage of the spatial arrangement of packing defects across aligned homologous structures.
Structural descriptors of protein-binding sites, such as hydrophobicity (25) , curvature (26) , and accessibility (27) are routinely used to guide inhibitor design. However, examination of the 814 nonredundant protein-inhibitor Protein Data Bank (PDB) complexes reveals that 488 of them have binding cavities with only average hydrophobicity (25) , not significantly higher than the rest of the surface. In such cases, ligand affinity is attributed to the intermolecular H-bonding propensities of the inhibitor, inferred from protein-substrate transition-state mimetics (21) (22) (23) (24) . However, charge screening in water renders putative intermolecular H-bonds unlikely promoters of protein-ligand association, unless water removal is favored at the interface by some preexisting feature on the surface of the protein (8) .
One obvious such feature is the solvent-exposed nonpolar moiety, except that, as stated above, such features occur infrequently on binding sites. A more common water-excluding feature has been recently identified. We have reported (3, 8, 18, 28, 29) that packing defects in proteins, the so-called ''dehydrons'' or underwrapped H-bonds, constitute sticky sites with a propensity to become dehydrated as a result of protein associations. The term ''wrapping'' indicates a clustering of nonpolar groups framing an anhydrous microenvironment. Dehydrons are signaled by insufficient intramolecular wrappers and promote protein-ligand associations that ''correct'' packing defects (21) . Their stickiness arises from the reduction of charge-screening when nonpolar groups come into proximity of H-bonds: water exclusion enhances and stabilizes preformed electrostatic interactions. A few (Ͻ7) nonpolar groups wrapping an H-bond simply hinder the hydration of the amide and carbonyl, but a sufficient number of wrappers make the hydration thermodynamically costly and introduce a compensation by enhancing the stability of the H-bond (3, 8, 18) .
We first show that in most PDB protein-inhibitor complexes, the ligand is in effect a wrapper of protein dehydrons, although it was not purposely designed to fulfill this role. In this way, the available data support the design concept. Subsequently, we introduce a wrapping technology and provide a proof of principle by demon-strating experimentally that targeting dehydrons that are not conserved across paralogs constitutes a useful strategy to enhance the selectivity of the inhibitory impact. Thus, the notion of packing similarity will be rigorously introduced and used selectively to modify a multiple-target inhibitor to achieve a higher specificity toward a particular target and subsequently to redirect its impact toward an alternative target.
Methods
Structure-Based Dehydron Identification. Packing defects in the form of dehydrons or underwrapped backbone H-bonds may be identified from the atomic coordinates of a protein structure in a single or multidomain chain or a protein complex in a PDB entry, according to these simple tenets (2-6). (i) The extent of intramolecular H-bond desolvation, , in a monomeric structure may be quantified as the number of nonpolar groups (carbonaceous, not covalently bonded to an electrophilic atom) contained within a desolvation domain. (ii) The desolvation domain is defined as two intersecting balls of fixed radius centered at the ␣-carbons of the residues paired by the backbone amide-carbonyl H-bond. (iii) Determining the extent of desolvation of an intramolecular H-bond within a protein-ligand or protein-protein complex requires that the count include nonpolar groups from the monomer itself as well as those from its binding partner(s). The statistics of H-bond wrapping depend on the choice of desolvation radius, but the tails of the distribution invariably single out the same dehydrons in a given structure over a 6.2-7 Å range in the adopted radius. In this work the value 6.4 Å was used.
In most (Ϸ92% of PDB entries) stable protein folds, at least two-thirds of the backbone H-bonds are wrapped on average by ϭ 26.6 Ϯ 7.5 nonpolar groups [or 14.0 Ϯ 3.7, counting only side-chain groups and excluding those from the H-bonded residue pair (8)]. Dehydrons are here defined as H-bonds whose extent of wrapping lies in the tails of the distribution, i.e., with 19 or fewer nonpolar groups in their desolvation domains, so their -value is one Gaussian dispersion below the mean. Dehydrons are dominant factors driving association in 38% of the PDB complexes (the number of dehydrons per 1,000 Å 2 at protein-protein interfaces is Ͼ3͞2 the average density on individual monomers). Furthermore, dehydrons constitute significant factors (interface dehydron density larger than average) in 92.9% of all PDB complexes (8) .
Given the inherent stickiness of packing defects in soluble proteins (8, 18) and the fact that interfacial water removal from a concave or flat region of the protein surface entails far less thermodynamic work than removal from a convex waterclathrated region (26), we infer that dehydrons in cavities are suitable targets for ligand design. These structural features become of paramount importance when the hydrophobicity of the cavity (25) is not significantly higher than the average for a soluble protein surface (8) .
Packing Homology. Assessing packing similarity among protein homologs requires comparing the microenvironments of backbone H-bonds (8) that can be effectively carried out following structural alignment (ref. 30 ; see also www.ncbi.nlm.nih.gov͞structure͞ CN3D͞cn3d.shtml). For a protein chain of length N, a matrix of dehydrons or underwrapped H-bonds D ij , i, j ϭ 1, 2, . . . , N is constructed by choosing D ij ϭ 1 if residues i and j are paired by a dehydron and D ij ϭ 0 otherwise. When the dehydron matrices for two proteins m and n are aligned, they are trimmed by restricting them to those residues that structurally align in a one-to-one correspondence. Then a Hamming distance M H (m, n) ϭ ¥ iϽj ͉D ij (m) Ϫ D ij (n)͉ is computed to serve as indicator of the packing similarity between proteins m, n. Given a collection of paralogs m, n ϭ 1, . . . , F, and its corresponding packing-similarity matrix M H ϭ [M H (m, n)], a packing-similarity tree (PST) may be easily constructed from the premise that the minimal pathway between protein-nodes m and n crosses a number of nodes equal to M H (m, n). Spectrophotometric Kinetic Assay. To determine the level of selectivity of drug inhibitors designed by adopting the wrapping technology, kinetic assays of the inhibition of multiple kinases have been conducted. To measure the rate of phosphorylation due to kinase activity in the presence of inhibitors, a standard spectrophotometric assay has been adopted (31) in which the adenosine diphosphate production is coupled to the NADH oxidation and determined by absorbance reduction at 340 nm. Reactions were carried out at 35°C in 500 l of buffer (100 mM Tris⅐HCl͞10 mM MgCl 2 ͞0.75 mM ATP͞1 mM phosphoenol pyruvate͞0.33 mM NADH͞95 units/ml pyruvate kinase, pH 7.5). The adopted peptide substrates (Invitrogen͞Biaffin) for kinase phosphorylation are AEEEIYG-EFEAKKKKG for unphosphorylated Brc-Abl (31), KVVEE-INGNNYVYIDPTQLPY for C-kit (32), GLARLIEDNEYTAR-EGAKFPI for LCK (33) , GCSPALKRSHSDSLDHDIFQL for Chk1 (34) , and EGLGPGDTTSTFCGTPNYIAP for Pdk1 (35) .
Results

Protein-Inhibitor Complexes and Wrapping of Packing Defects.
The interfaces of the 814 protein-inhibitor PDB complexes were reexamined to determine whether inhibitors were ''dehydron wrappers,'' that is, whether nonpolar groups of inhibitors penetrated the desolvation domain of dehydrons. This feature was found in 631 complexes and invariably found in the 488 complexes whose binding cavities presented average or no surface hydrophobicity (25) . Figs. 1 and 2 show such wrapping for the HIV-1 protease (21, 36) and urokinase-type plasminogen activator (23), respectively. The inhibitor contribution to improve the protein packing is not fortuitous because the substrate must be anchored and water must be expelled from the enzymatic site. Thus, wrapping of dehydrons is an effective, if unintended, strategy for drug design (6) .
The Merck inhibitor Indinavir (Crixivan) bound to the functionally dimeric HIV-1 protease (PDB ID code 2BPX) is shown in Fig.  1 (21, 36) . The dehydrons are marked in green. On each monomer, these dehydrons are backbone H-bonds between these residue pairs: Ala-28-Arg-87, Asp-29-Asn-88, Gly-49-Gly-52, and Gly-16-Gln-18. The cavity associated with substrate binding contains the first three dehydrons, with dehydron 49-52 located in the flap and dehydrons 28-87 and 29-88 adjacent to the catalytic site (Asp-25) to anchor the substrate. This ''sticky track'' determined by dehydrons 28-87 and 29-88 is required to align the substrate peptide across the cavity as needed for nucleophilic attack by the Asp-25. The flap, conversely, needs an exposed, and hence labile, H-bond to confer the flexibility associated with the gating mechanism. The lack of protection on the flap (49-52) H-bond becomes the reason for its stickiness, because the bond can be strengthened by the exogenous removal of surrounding water (Fig. 1C) . The positioning of all three dehydrons in the cavity (six in the dimer) promotes inhibitor association ( Fig. 1 A and B) .
Indinavir is a wrapper of packing defects in the enzymatic cavity: it contributes 12 desolvating groups to the 49-52 H-bond (Fig. 1C) , 10 to the 28-87 H-bond, and 8 to the 29-88 H-bond. All functionally relevant residues are either polar or expose the polarity of the peptide backbone (Asp-25, Thr-26, Gly-27, Ala-28, Asp-29, Arg-87, Asn-88, Gly-49, and Gly-52) and thus are not themselves promoters of association to hydrophobic groups of the ligand. The strategic position of dehydrons involving these residues in their microenvironments becomes a decisive factor to drive water removal or charge descreening required in facilitating the enzymatic nucleophilic attack. Fig. 2 shows an inhibitor acting as wrapper of packing defects in its complexation with the urokinase-type plasminogen activator (PDB ID code 1C5W), a protease associated with tumor metastasis and invasion (23) . Strikingly, none of the hydrophobic residues in the cavity contributes to the inhibitor binding (Fig. 2C) .
Enhancing Specificity by Targeting Packing Defects. Central to drug design is the minimization of toxic side effects. Because paralog proteins are likely to share common domain structures (37), the possibility of multiple binding partners for a given protein inhibitor arises, unless it specifically targets nonconserved features. This problem may be circumvented by targeting dehydrons because, in contrast to the fold, the wrapping is generally not conserved (3), making dehydron wrapping a selectivity filter in drug design.
To determine whether dehydron targeting is likely to reduce side effects, we first investigated the extent of conservation of dehydrons across human paralogs in PDB. The paralogs for every crystallized protein-inhibitor complex were identified, and dehydron patterns at binding cavities were compared. A 30% minimal sequence alignment was required for paralog identification. Packing defects were found to be a differentiating marker in paralogs of 527 of the investigated 631 proteins crystallized in complex with inhibitors. Protein chains are often reported in complexes with different inhibitors.
The PDB contains 440 redundancy-free pairs of human paralogs. Of these, 308 involve some of the 527 proteins with binding dehydrons. In 269 pairs, the intramolecular wrapping at the binding cavity differs in the location or presence of at least one dehydron, and in 203 pairs, the difference extends to two or more dehydrons. Thus, the probability of avoiding side effects by selectively wrapping packing defects is estimated at 88% (269 of 308).
For instance, ␣-thrombin (PDB ID code 1A3E) (38) , a paralog of the plasminogen activator (PDB ID code 1C5W), shares a common domain structure but a different dehydron pattern (Fig.  3) . Although the inhibitor of the ␣-thrombin is a wrapper of cavity dehydrons (Fig. 3B) , additional specificity would have been gained if the inhibitor had been tailored to target the unique dehydron pattern of the cavity (compare Figs. 2 A and 3B) . Specifically, the Ser-195-Gly-197 dehydron in ␣-thrombin becomes well wrapped in the plasminogen activator.
Poor Dehydron Wrappers Make Poor Drugs. The natural product staurosporine has been singled out as the ligand inhibitor most promiscuously interactive with the human kinome (39) . Its complexes, extensively reported in the PDB, reveal inhibitory impact over the following kinases: HCDK, Csk, Phosphoinositide 3k, Cdk2, Pcdk1, Pcdk2, Srck, Chk, Map Kap k2, Gsk-3␤, lymphocyte kinase (Lck), Itk, Zap70 k, cAMP-dependent protein kinase, Syk tyrosine k, Jak3 k, Pim1 k, and Ser-Thr protein kinase 16 . We have examined all 96 staurosporine-protein PDB complexes and found no instance of the inhibitor acting as dehydron wrapper. All interactions were hydrophobic, involving nonpolar groups on the protein surface. An illustration of such binding is given in Fig. 4 , where the Syk tyrosine kinase-staurosporine complex (PDB ID code 1XBC) is shown to hinge on three pivotal hydrophobic interactions engaging Phe-382, Val-385, and Leu-377. Note that staurosporine does not wrap the single dehydron closest to the binding site, Gly-380-Gly-382. Thus, because surface hydrophobic residues tend to be conserved as markers for interactivity and staurosporine does not discriminate among packing differences in the kinome, its promiscuity becomes entirely expected, and so is its uselessness as a therapeutic agent.
Wrapping as a Selectivity Filter: Proof of Principle. We now provide a proof of principle of the enhanced selectivity achieved with the proposed wrapping technology. Because of the evolutionary proximity of kinases, side effects arising from off-target ligand binding often arise with kinase inhibitors, especially in cancer therapy (39) . Thus, a need arises to sharpen the binding affinity within the pharmacokinome associated with a specific drug. For example, selective inhibition of the Brc-Abl (Abelson tyrosine kinase), the fusion product of a chromosomal translocation, is crucial to treat chronic myeloid leukemia (31) . Brc-Abl has been proven to be a target for the potent inhibitor Gleevec (31) but is not its only target (39) . Of the alternative targets with reported structure, the C-kit tyrosine kinase can be a binding partner, making Gleevec a therapeutic agent for colorectal cancer (40, 41) . In addition, Gleevec binds tightly to the Lck (33). Thus, we sought to modify Gleevec to improve its selectivity for Brc-Abl by targeting dehydrons not conserved across paralogs.
The protein-inhibitor complex with PDB ID code 1FPU (Fig.  5A ) reveals three electrostatic interactions in Brc-Abl, the dehydrons Gly-249-Gln-252 and Gln-300-Glu-316 and the salt bridge Lys-271-Glu-286, that can be better wrapped by methylating Gleevec at the positions indicated. Thus, methylation at positions I, II, and III would presumably improve the wrapping of dehydrons 249-252 and 300-316 and salt bridge 271-286, respectively. A structural alignment of the paralogs of Brc-Abl was performed using the program CN3D (30) to investigate the microenvironment conservation for these intramolecular interactions. The six kinases reported in PDB that aligned with Brc-Abl are C-kit (PDB ID code 1T45), Lck (3LCK), Pdk1 kinase (1UVR), Cdc42-associated Tyr kinase Ack1 (1U54), EGF receptor kinase (1M17), and the checkpoint kinase Chk1 (1IA8). The alignment is shown in Fig. 5B . The dehydron 249-252 (crankshaft-like kink marked in yellow on Fig.  5B ) is not conserved in any of the six paralogs of Brc-Abl, whereas the dehydron 300-316 becomes well wrapped in the paralogs. Conversely, the microenvironment of the salt bridge 271-286 is conserved.
The packing similarities among all seven paralogs are quantified by introducing a ''packing homology.'' Thus, a distance between two aligned protein structures is established by first determining their respective dehydron matrices and then computing the Hamming distance between the aligned matrices. The ij-entry is 1 if residues i and j are paired by a dehydron; otherwise, the entry is 0. A PST then may be built so that the minimum number of nodes along a walk from one protein node to another is proportional to their Hamming distance. The resulting PST (Fig. 5C ) is identical to the phylogenetic tree limited to the seven proteins (42) , implying that dehydron structure alone encodes functional differences in proteins. We also have restricted the PST computation to the H-bonds͞dehydrons in Brc-Abl, which become wrapped by Gleevec upon association (Fig. 5C ). Adopting this restricted measure, the closest proteins to Brc-Abl become Lck and C-kit, precisely the alternative Gleevec targets with reported structure.
To enhance affinity and selectivity for Brc-Abl, we modified the inhibitor methylating at positions I and II (Fig. 5D) (43) . To test whether the specificity and affinity for Brc-Abl improved, we conducted a spectrophotometric assay to measure the phosphorylation rate of peptide substrates (31) (32) (33) (34) (35) in the presence of the kinase inhibitor at different concentrations. As indicated in Fig. 5E , the inhibition of unphosphorylated Brc-Abl by the wrapper of the 249-252 and 300-316 dehydrons (the I,II methylation product) improved over Gleevec levels. Furthermore, the inhibitory impact of the dehydron wrapper became selective for Brc-Abl vis-à-vis C-kit and Lck. Dehydrons 249-252 and 300-316 are absent in the latter kinases, and consistently, the drug designed to better wrap them has very low inhibitory impact against C-kit and Lck. Finally, neither Gleevec nor its modified version showed detectable inhibitory impact on the remaining paralogs, Chk1, Pdk1, for which substrate peptides have been reported. Selectivity Switch Based on Packing Differences. In accord with the fact that packing defects may serve as selectivity filters, we may take advantage of packing differences across paralogs to create a selectivity switch. A structural alignment (Fig. 5B) of the Brc-Abl and C-kit kinases reveals that dehydron Gly-249-Gln-252 in Brc-Abl (Fig. 5A ) maps onto dehydron Cys-673-Gly-676 in C-kit (Fig. 6A ), spatially displaced with respect to the former. Given the relative position of the 673-676 dehydron of C-kit with respect to Gleevec in the protein-inhibitor complex (PDB ID code 1T46), we may determine which modification of Gleevec would selectively direct its impact toward C-kit. By methylating Gleevec at the para position (IV) in the terminal ring rather than the ortho position (I, Fig. 5A ), the inhibitor becomes a selective wrapper of the packing defect in C-kit, while it ceases to wrap the 249-252 dehydron in Brc-Abl. The inhibitory impact of Gleevec methylated at positions II,IV is apparent in the phosphorylation rates obtained from the spectrophotometric assay on the same five kinases studied previously (Figs. 5E and 6B). The inhibitory impact of the II,IV Gleevec variant is now concentrated on C-kit, not Brc-Abl. Thus, by redesigning Gleevec according to the wrapping differences between Brc-Abl and C-kit, we redirected the inhibitory impact from one kinase to the other. Both sets of experiments reveal that the wrapping technology may introduce a selectivity switch in inhibitor design.
Discussion
This work substantiates a previously undescribed concept in inhibitor design: packing defects (dehydrons) in proteins may be used as targets for ligands designed to wrap them. Because dehydrons are generally not conserved across homolog proteins, the inhibitory impact of this wrapping technology is likely to be highly selective.
Functional differences across homolog proteins sharing a common fold are very frequent in biology. Previous studies revealed that the wrapping constitutes a molecular dimension explored when evolution is constrained to preserve the fold for functional reasons. Thus, it is likely that packing differences across paralogs are indicative of the functional fine tuning that needs to be discriminated in drug therapy. As this work reveals, such packing differences offer a previously undescribed control in constructing the selectivity filters and selectivity switches that may endow the wrapping technology with a high therapeutic value. 
